SCHEDULE: NewcelX CEO Ronen Twito Discloses 6% Stake Post-Merger

NewcelX Ltd.'s Executive Chairman and CEO, Ronen Twito, has filed a Schedule 13D disclosing beneficial ownership of 6.0% of the company's common shares following the merger of NLS Pharmaceutics and Kadimastem.

Summary

• Ronen Twito, Executive Chairman and CEO of NewcelX Ltd., beneficially owns 272,399 common shares, representing 6.0% of the company's outstanding shares.
• This ownership includes 246,508 common shares and 25,891 common shares issuable upon vesting of restricted share units (RSUs) exercisable within 60 days of October 30, 2025.
• The shares were acquired as a result of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., completed in 2025, which resulted in the formation of NewcelX Ltd.
• In connection with the merger, 349,331 Kadimastem ordinary shares previously owned by Mr. Twito were converted into 246,508 NewcelX Common Shares, and 36,690 Kadimastem RSUs were converted into 25,891 NewcelX RSUs.
• Mr. Twito's annual salary is $398,797, which will increase to $445,714 upon NewcelX completing a capital raise exceeding $10 million.
• He also received a one-time bonus of $100,000 for the merger closing.

Sentiment

Score: 7

Explanation: The filing details the beneficial ownership of a key executive post-merger, indicating his significant stake and commitment to the newly formed company. The compensation structure, including a bonus and a salary increase contingent on a future capital raise, suggests a forward-looking growth strategy.

Positives

• Executive Chairman and CEO Ronen Twito holds a significant 6.0% beneficial ownership stake in NewcelX Ltd., aligning his interests with shareholders.
• Mr. Twito received a $100,000 one-time bonus in connection with the merger closing.
• His annual salary is set to increase from $398,797 to $445,714 upon the successful completion of a capital raise exceeding $10 million, indicating potential future compensation growth tied to company financing.

Future Outlook

The Executive Chairman and CEO's annual salary is structured to increase from $398,797 to $445,714 upon NewcelX Ltd. successfully completing a capital raise exceeding $10 million following the merger. This indicates a future financial milestone tied to executive compensation.

Management Comments

• "The Reporting Person holds all securities of the Issuer for investment purposes only."
• "The Reporting Person serves as the Executive Chairman and Chief Executive Officer of NewcelX and, in such capacities, will be involved in reviewing transactions that may result in operational, strategic, financial or governance changes for NewcelX and may have influence over the corporate activities of NewcelX."

Industry Context

This filing is a standard disclosure of beneficial ownership by a key executive following a corporate merger. It reflects the integration phase of the combined entity, NewcelX Ltd., formed from NLS Pharmaceutics and Kadimastem. The compensation structure, including a salary increase contingent on a capital raise, is common in growth-oriented companies, particularly in the biotechnology or pharmaceutical sectors where significant funding is often required for R&D and commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• The merger transaction itself, where Ronen Twito's shares and RSUs in Kadimastem were converted into NewcelX securities, constitutes a related party transaction given his executive role in both entities.
• Ronen Twito's employment agreement, including his annual salary and a one-time merger bonus, is a related party transaction between the company and its CEO.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a key executive's significant ownership stake (6.0%), which can align management and shareholder interests. The potential for a future capital raise could dilute existing shareholders but also fund growth initiatives.
• Employees: The merger led to the formation of NewcelX, impacting the organizational structure and potentially roles within the combined entity.
• Management: Ronen Twito's compensation structure, including a bonus and a salary increase tied to a capital raise, directly impacts his financial incentives and motivation.

Next Steps

• Completion of a capital raise exceeding $10 million by NewcelX Ltd.

Key Dates

Recommendation

This Schedule 13D filing primarily provides transparency on a key executive's beneficial ownership and compensation structure following a merger. It confirms the CEO's significant stake and outlines future compensation tied to a capital raise, which could be a positive signal for future growth funding. However, it does not contain new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate as it's an informational filing that confirms existing corporate actions and executive alignment without providing new fundamental catalysts for a change in investment thesis.

Keywords

NewcelX Ltd., NLS Pharmaceutics Ltd., Kadimastem Ltd., Ronen Twito, Schedule 13D, Beneficial Ownership, Merger, Common Shares, Restricted Share Units, Executive Chairman, Chief Executive Officer, Capital Raise